These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11069253)

  • 21. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
    Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy.
    Haubrich RH; Currier JS; Forthal DN; Beall G; Kemper CA; Johnson D; Dubé MP; Hwang J; Leedom JM; Tilles J; McCutchan JA;
    Clin Infect Dis; 2001 Oct; 33(7):1060-8. PubMed ID: 11528581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
    Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
    J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
    Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
    Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.
    Sei S; Sandelli SL; Theofan G; Ratto-Kim S; Kumagai M; Loomis-Price LD; Cox JH; Jarosinski P; Walsek CM; Brouwers P; Venzon DJ; Xu J; Pizzo PA; Moss RB; Robb ML; Wood LV
    J Infect Dis; 1999 Sep; 180(3):626-40. PubMed ID: 10438349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.
    Fletcher CV; DeVille JG; Samson PM; Moye JH; Church JA; Spiegel HM; Palumbo P; Fenton T; Smith ME; Graham B; Kraimer JM; Shearer WT;
    J Allergy Clin Immunol; 2007 Mar; 119(3):747-50. PubMed ID: 17336619
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.
    Jacobson JM; Israel RJ; Lowy I; Ostrow NA; Vassilatos LS; Barish M; Tran DN; Sullivan BM; Ketas TJ; O'Neill TJ; Nagashima KA; Huang W; Petropoulos CJ; Moore JP; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):423-9. PubMed ID: 14742190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroreversion in vertically HIV-1-infected children treated early and efficiently: rule or exception?
    Eberle J; Notheis G; Blattmann C; Jung J; Buchholz B; Korn K; Kulozik AE; Schnitzler P
    AIDS; 2010 Nov; 24(17):2760-1. PubMed ID: 20980873
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children.
    Starr SE; McFarland EJ; Muresan P; Fenton T; Pitt J; Douglas SD; Deveikis A; Levin MJ; Rathore MH;
    AIDS; 2003 Oct; 17(15):2181-9. PubMed ID: 14523275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates.
    Gauduin MC; Allaway GP; Olson WC; Weir R; Maddon PJ; Koup RA
    J Virol; 1998 Apr; 72(4):3475-8. PubMed ID: 9525686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PRO 542. CD4 IgG2.
    Drugs R D; 1999 Nov; 2(5):350-1. PubMed ID: 10728479
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex.
    Collier AC; Coombs RW; Katzenstein D; Holodniy M; Gibson J; Mordenti J; Izu AE; Duliege AM; Ammann AJ; Merigan T
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):150-6. PubMed ID: 7552478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapies.
    Pincus SH; Fang H; Wilkinson RA; Olson WC; Marcotte TK
    AIDS Res Hum Retroviruses; 2003 Oct; 19(10):901-8. PubMed ID: 14585222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recombinant CD4-IgG in the treatment of AIDS and correlated syndromes: 1st stage of the study].
    Di Nola F
    Minerva Pediatr; 1992; 44(7-8):385. PubMed ID: 1406513
    [No Abstract]   [Full Text] [Related]  

  • 39. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
    Shearer WT; DeVille JG; Samson PM; Moye JH; Fletcher CV; Church JA; Spiegel HM; Palumbo P; Fenton T; Smith ME; Graham B; Kraimer JM; Olson WC
    J Allergy Clin Immunol; 2006 Aug; 118(2):518-21. PubMed ID: 16890780
    [No Abstract]   [Full Text] [Related]  

  • 40. [CD4-derivatives therapy of HIV carriers].
    Mizukami T; Mitsuya H
    Nihon Rinsho; 1993 Sep; 51 Suppl():327-33. PubMed ID: 8271399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.